FDA Investigator Hamet M Toure, PharmD MPH
Hamet M Toure, PharmD MPH has inspections in 3 countries as of 20 Jul 2023. Hamet M Toure, PharmD MPH has collaborated with a combined 1009 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
3
Last Inspection Date:
20 Jul 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
Belgium,
Germany,
Malaysia
Co-Investigator(s):
Alice S Tsao,
Anjali Shukla, PhD,
Azza Talaat,
Caryn M Mcnab,
Charisse K Green,
Charles L Zhou,
Daniel J Lahar,
Daniel Lahar,
David M Beltran,
Dr. Robert C Horan, MD,
Eileen A Liu,
Ephrem Hunde, PhD,
Hamet Toure, PharmD MPH,
Jacqueline Mdiaz Albertini,
James L Dunnie, Jr,
Jose E Melendez, DDC,
Katherine D Adams,
Katherine Szestypalow,
Kimberley A Hoefen,
Liatte Kreuger, PharmD,
Linda F Murphy,
Madushini Dharmasena, PhD,
Maryam Tabatabaie,
Michael E Maselli,
Mihaly S Ligmond,
Mra M Barbosar,
Mra Mcculloughj,
Nancy A Bellamy,
Omotunde O Osunsanmi,
Patsy J Domingo,
Patty P Kaewussdangkul,
Richard Ledwidge (nmi), PhD,
Robert D Tollefsen,
Roger F Zabinski,
Rong Guo,
Russell K Riley,
Santos E Camara,
Seifert Seifert, Wayne E,
Sharon K Thoma, PharmD,
Shawn E Larson,
Simone E Pitts,
Thomas J Arista,
Thomas S Arista,
Thuy T Nguyen, LCDR,
Tracey L Harris,
Uduak M Inokon,
Vidya B Pai,
Wayne E Seifert,
Wendy G Tan, PhD,
Xiaokuang Lai, PhD,
Yetao Jin, PhD,
Zabinski Zabinski, Roger F,
Zhihao Qiu (Peter), PhD
Hamet M Toure, PharmD MPH's Documents
Publish Date | Document Type | Title |
---|---|---|
April, 2023 | FDA 483 | UCB Pharma S.A. - Form 483, 2023-04-21 |
August, 2022 | FDA 483 | BIOCON SDN.BHD. - Form 483, 2022-08-30 |
April, 2023 | EIR | UCB Pharma S.A. - EIR, 2023-07-28 |
November, 2023 | FDA 483 | Patheon Biologics LLC - Form 483, 2023-11-10 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more